Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka, D van der Heijde… - Annals of the …, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective</jats: title>< jats: p> To evaluate the efficacy and safety
of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis …
of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis …
[引用][C] Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka… - Annals of the …, 2021 - espace.library.uq.edu.au
To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib
versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka… - Annals of the …, 2021 - researchinformation.amsterdamumc …
To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib
versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka… - Annals of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
[HTML][HTML] Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka… - Annals of the …, 2021 - ncbi.nlm.nih.gov
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka… - Annals of the …, 2021 - hal.science
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
[PDF][PDF] Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka… - Annals of the …, 2021 - ard.bmj.com
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
B Combe, A Kivitz, Y Tanaka… - Annals of the …, 2021 - search.proquest.com
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
[PDF][PDF] Ki itz
B Combe - Tanaka,., Hei de, D. an der, Simon,.., Baraf, HSB …, 2021 - core.ac.uk
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …